Related Experiment Video
Updated: Aug 16, 2026
Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay
Published on: October 18, 2016
Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory
Jessica Koenigsknecht-Talboo1, Gary E Landreth
1Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Abstract:
Microglia undergo a phenotypic activation in response to fibrillar beta-amyloid (fAbeta) deposition in the brains of Alzheimer's disease (AD) patients, resulting in their elaboration of inflammatory molecules. Despite the presence of abundant plaque-associated microglia in the brains of AD patients and in animal models of the disease, microglia fail to efficiently clear fAbeta deposits. However, they can be induced to do so during Abeta vaccination therapy attributable to anti-Abeta antibody stimulation of IgG receptor (FcR)-mediated phagocytic clearance of Abeta plaques. We report that proinflammatory cytokines attenuate microglial phagocytosis stimulated by fAbeta or complement receptor 3 and argue that this may, in part, underlie the accumulation of fAbeta-containing plaques within the AD brain. The proinflammatory suppression of fAbeta-elicited phagocytosis is dependent on nuclear factor kappaB activation. Significantly, the proinflammatory cytokines do not inhibit phagocytosis elicited by antibody-mediated activation of FcR, which may contribute to the efficiency of Abeta vaccination-based therapy. Importantly, the proinflammatory suppression of fAbeta phagocytosis can be relieved by the coincubation with anti-inflammatory cytokines, cyclooxygenase inhibitors, ibuprofen, or an E prostanoid receptor antagonist, suggesting that proinflammatory cytokines induce the production of prostaglandins, leading to an E prostanoid receptor-dependent inhibition of phagocytosis. These findings support anti-inflammatory therapies for the treatment of AD.
Insights
Proinflammatory cytokines impair microglia's ability to clear amyloid plaques in Alzheimer's disease (AD). Anti-inflammatory treatments may help restore this function, offering new therapeutic avenues for AD.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Microglia, the brain's immune cells, activate in Alzheimer's disease (AD) but fail to clear fibrillar beta-amyloid (fAbeta) plaques.
- Microglial clearance of fAbeta can be induced by Abeta vaccination therapy via Fc receptor (FcR)-mediated phagocytosis.
Purpose of the Study:
- To investigate how proinflammatory cytokines affect microglial phagocytosis of fAbeta.
- To explore the mechanisms underlying the impaired clearance of fAbeta in AD brains.
- To identify potential therapeutic targets for enhancing microglial function in AD.
Main Methods:
- Assessed microglial phagocytosis of fAbeta and complement receptor 3 (CR3) in the presence of proinflammatory cytokines.
- Investigated the role of nuclear factor kappaB (NF-κB) activation in cytokine-mediated suppression.
- Examined the effect of proinflammatory cytokines on FcR-mediated phagocytosis.
- Tested the efficacy of anti-inflammatory agents in reversing cytokine-induced suppression.
Main Results:
- Proinflammatory cytokines significantly attenuate microglial phagocytosis of fAbeta and CR3, dependent on NF-κB activation.
- This suppression does not affect FcR-mediated phagocytosis, suggesting a mechanism for Abeta vaccination therapy's success.
- The inhibitory effect is mediated by prostaglandin production, acting through E prostanoid receptors.
- Coincubation with anti-inflammatory cytokines, NSAIDs like ibuprofen, or E prostanoid receptor antagonists reversed the suppression.
Conclusions:
- Proinflammatory cytokines contribute to fAbeta plaque accumulation in AD by inhibiting microglial phagocytosis.
- The findings highlight a prostaglandin-mediated pathway for this inhibition, dependent on E prostanoid receptors.
- Targeting this pathway with anti-inflammatory therapies holds promise for treating Alzheimer's disease.
